Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 29;5(49):eabd5709.
doi: 10.1126/sciimmunol.abd5709.

SARS-CoV-2 seroprevalence among parturient women in Philadelphia

Dustin D Flannery #  1   2   3 , Sigrid Gouma #  4 , Miren B Dhudasia  1   3 , Sagori Mukhopadhyay  1   2   3 , Madeline R Pfeifer  1 , Emily C Woodford  1 , Jeffrey S Gerber  2   3   5 , Claudia P Arevalo  4 , Marcus J Bolton  4 , Madison E Weirick  4 , Eileen C Goodwin  4 , Elizabeth M Anderson  4 , Allison R Greenplate  6   7 , Justin Kim  6   7 , Nicholas Han  6   7 , Ajinkya Pattekar  6   8 , Jeanette Dougherty  6   7 , Oliva Kuthuru  6   7 , Divij Mathew  6   7 , Amy E Baxter  6   7 , Laura A Vella  5   6 , JoEllen Weaver  9 , Anurag Verma  10 , Rita Leite  11 , Jeffrey S Morris  12 , Daniel J Rader  9   10 , Michal A Elovitz  6   11 , E John Wherry  6   7 , Karen M Puopolo  13   2   3 , Scott E Hensley  14   6
Affiliations

SARS-CoV-2 seroprevalence among parturient women in Philadelphia

Dustin D Flannery et al. Sci Immunol. .

Abstract

Limited data are available for pregnant women affected by SARS-CoV-2. Serological tests are critically important for determining SARS-CoV-2 exposures within both individuals and populations. We validated a SARS-CoV-2 spike receptor binding domain serological test using 834 pre-pandemic samples and 31 samples from COVID-19 recovered donors. We then completed SARS-CoV-2 serological testing of 1,293 parturient women at two centers in Philadelphia from April 4 to June 3, 2020. We found 80/1,293 (6.2%) of parturient women possessed IgG and/or IgM SARS-CoV-2-specific antibodies. We found race/ethnicity differences in seroprevalence rates, with higher rates in Black/non-Hispanic and Hispanic/Latino women. Of the 72 seropositive women who also received nasopharyngeal polymerase chain reaction testing during pregnancy, 46 (64%) were positive. Continued serologic surveillance among pregnant women may inform perinatal clinical practices and can potentially be used to estimate exposure to SARS-CoV-2 within the community.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Geographical distribution of women tested for SARS-CoV-2 antibodies. Most serum specimens analyzed were from women living in areas within or immediately bordering the city of Philadelphia. Location of birth hospitals where serum samples were collected are shown as red crosses.
Fig. 2
Fig. 2. Serum SARS-CoV-2 antibody levels in COVID-19 pandemic and pre-pandemic individuals.
(A-B) Relative levels of SARS-CoV-2 IgG (A) and IgM (A) in serum collected before the COVID-19 pandemic (n = 834) and serum collected from COVID-19 recovered donors (n = 31). (C-D) Relative levels of SARS-CoV-2 IgG (C) and IgM (D) in serum collected from pregnant women from 2009-2012 (n = 140) and from April 4-June 3, 2020 (n = 1,293). Dashed lines indicate 0.48 arbitrary units, which was used to distinguish positive versus negative samples (see Methods). Serum samples that were below the cutoff for seropositivity were assigned an antibody level of 0.40 arbitrary units.
See this image and copyright information in PMC

Update of

  • SARS-CoV-2 Seroprevalence Among Parturient Women.
    Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, Gerber JS, Arevalo CP, Bolton MJ, Weirick ME, Goodwin EC, Anderson EM, Greenplate AR, Kim J, Han N, Pattekar A, Dougherty J, Kuthuru O, Mathew D, Baxter AE, Vella LA, Weaver J, Verma A, Leite R, Morris JS, Rader DJ, Elovitz MA, Wherry EJ, Puopolo KM, Hensley SE. Flannery DD, et al. medRxiv [Preprint]. 2020 Jul 10:2020.07.08.20149179. doi: 10.1101/2020.07.08.20149179. medRxiv. 2020. Update in: Sci Immunol. 2020 Jul 29;5(49):eabd5709. doi: 10.1126/sciimmunol.abd5709. PMID: 32676623 Free PMC article. Updated. Preprint.

References

    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323, 1061 (2020). 10.1001/jama.2020.1585 - DOI - PMC - PubMed
    1. Abbasi J., The Promise and Peril of Antibody Testing for COVID-19. JAMA 323, 1881 (2020). 10.1001/jama.2020.6170 - DOI - PubMed
    1. D. Crook, Evaluation of antibody testing for SARS-CoV-2 using ELISA and lateral flow immunoassays, medRxiv, (2020). 10.1101/2020.04.15.20066407 - DOI
    1. J. D. Whitman, J. Hiatt, C. T. Mowery, B. R. Shy, R. Yu, T. N. Yamamoto, U. Rathore, G. M. Goldgof, C. Whitty, J. M. Woo, A. E. Gallman, T. E. Miller, A. G. Levine, D. N. Nguyen, S. P. Bapat, J. Balcerek, S. Bylsma, A. M. Lyons, S. Li, A. W. Wong, E. M. Gillis-Buck, Z. B. Steinhart, Y. Lee, R. Apathy, M. J. Lipke, J. A. Smith, T. Zheng, I. C. Boothby, E. Isaza, J. Chan, D. D. Acenas, J. Lee, T. A. Macrae, T. S. Kyaw, D. Wu, D. L. Ng, W. Gu, V. A. York, H. A. Eskandarian, P. C. Callaway, L. Warrier, M. E. Moreno, J. Levan, L. Torres, L. Farrington, R. Loudermilk, K. Koshal, K. C. Zorn, W. F. Garcia-Beltran, D. Yang, M. G. Astudillo, B. E. Bernstein, J. A. Gelfand, E. T. Ryan, R. C. Charles, A. J. Iafrate, J. K. Lennerz, S. Miller, C. Y. Chiu, S. L. Stramer, M. R. Wilson, A. Manglik, C. J. Ye, N. J. Krogan, M. S. Anderson, J. G. Cyster, J. D. Ernst, A. H. B. Wu, K. L. Lynch, C. Bern, P. D. Hsu, A. Marson, Test performance evaluation of SARS-CoV-2 serological assays, medRxiv, 2020.04.25.20074856 (2020). - PubMed
    1. Vital Statistics Annual Report (available at https://www.health.pa.gov/topics/HealthStatistics/VitalStatistics/PAVita...).

Publication types

MeSH terms

LinkOut - more resources